Academic Unit of Neurology, Room 5.41 Trinity Biomedical Science Institute, Trinity College Dublin, Pearse Street, Dublin 2, Ireland.
Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
Nat Rev Dis Primers. 2017 Oct 5;3:17071. doi: 10.1038/nrdp.2017.71.
Amyotrophic lateral sclerosis (ALS), also known as motor neuron disease, is characterized by the degeneration of both upper and lower motor neurons, which leads to muscle weakness and eventual paralysis. Until recently, ALS was classified primarily within the neuromuscular domain, although new imaging and neuropathological data have indicated the involvement of the non-motor neuraxis in disease pathology. In most patients, the mechanisms underlying the development of ALS are poorly understood, although a subset of patients have familial disease and harbour mutations in genes that have various roles in neuronal function. Two possible disease-modifying therapies that can slow disease progression are available for ALS, but patient management is largely mediated by symptomatic therapies, such as the use of muscle relaxants for spasticity and speech therapy for dysarthria.
肌萎缩侧索硬化症(ALS),又称运动神经元病,其特征是上下运动神经元同时退化,导致肌肉无力,最终瘫痪。直到最近,ALS 主要被归类于神经肌肉领域,尽管新的成像和神经病理学数据表明非运动神经元轴索也参与了疾病的病理过程。在大多数患者中,ALS 的发病机制尚不清楚,尽管有一部分患者患有家族性疾病,并携带在神经元功能中具有各种作用的基因突变。目前有两种可能的疾病修饰疗法可减缓疾病进展,但 ALS 的患者管理主要通过对症治疗来实现,例如使用肌肉松弛剂治疗痉挛和言语治疗治疗构音障碍。